Asthma and COVID-19: What do we know?

Sarioglu, Nurhan

doi:10.5578/tt.69775

Asthma and COVID-19: What do we know?

Nurhan SARIOĞLU (Balıkesir Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Balıkesir, Türkiye)

Tüberküloz ve Toraks

0 0

Yıl: 2020 Cilt: 68 Sayı: 2 Sayfa Aralığı: 141 - 147 Metin Dili: İngilizce DOI: 10.5578/tt.69775 İndeks Tarihi: 22-11-2020

Asthma and COVID-19: What do we know?

Öz:

There are limited data about the coexistence of asthma and the Coronavirusdisease-2019 (COVID-19). The COVID-19 pandemic is a new disease for thewhole world. In this study, we aimed to examine the published case serieswith the COVID-19 and asthma coexistence, by reviewing existing studies andother publications. We discussed the suggestions of guidelines such as TheGlobal Initiative for Asthma (GINA), The National Institute for Health andCare Excellence (NICE), and the Canadian Respiratory Guideline about themanagement of asthma during the COVID-19 pandemic and the experiencesof different countries. We analyzed the publications, reports, and expert opinions about asthma and COVID-19, that were released and expressed from theonset of the disease in Wuhan. In this review, we aimed to summarize theapproach to patients with asthma during the pandemic and to make recommendations concerning it.

Anahtar Kelime:

Astım ve COVID-19: Ne biliyoruz?

Öz:

Astım ve koronavirüs hastalığı-2019 (COVID-19) birlikteliği hakkında sınırlı sayıda veri bulumaktadır. COVID-19 pandemisi tüm dünyanın yeni tecrübe ettiği bir hastalıktır. Biz burada, astım ve COVID-19 ile ilgili yayınlanmış olan olgu serilerini ve varsa yapılmış çalışmaları ve diğer yazıları irdelemeye çalıştık. “The Global Initiative for Asthma (GINA)”, “The National Institute for Health and Care Excellence (NICE)” ve “Canadian Respiratory Guideline” gibi rehberlerin COVID-19 pandemisi sırasındaki astım yönetimi konusundaki önerilerini ve farklı ülkelerdeki deneyimleri ele aldık. Hastalığın Wuhan’da ilk ortaya çıkışından bu güne kadar astım ve COVID-19 hakkında bildirilen yayınları, raporları ve uzman görüşlerini inceledik. Bu yazıda pandemi sırasında astım hastalarına yaklaşımı özetlemeye ve önerileri sunmaya çalıştık.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available from:https:// www.who.int/dg/ speeches/detail/ who-director-general-s-opening-remarksat-the-media-briefing-on-covid-19---11-march-2020, Accessed 15th Mar 2020
2. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) situation summary Available from: https://www.cdc.gov/coronavirus/2019-ncov/ index.html, Accessed 15th Mar 2020
3. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China. Allergy 2020. doi: 10.1111/ all.14238.
4. Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet 2019;394:407-18.
5. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020 pii: S0091- 6749(20)30495-4.
6. Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. Eleven faces of coronavirus disease 2019. Allergy 2020. doi: 10.1111/all.14289.
7. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55(5). pii: 2000547. doi: 10.1183/13993003.00547- 2020
8. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020;69(15):458- 64. doi: 10.15585/ mmwr.mm6915e3.
9. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, et l. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020. doi: 10.1001/ jama.2020.6775
10. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med 2020;8(1):e35. eCollection 2020.
11. Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. COVID- 19 SARS-CoV-2 preprints from medRxiv and bioRxiv 2020. doi: 10.1101/2020.05.06.20092999
12. Konopka KE, Wilson A, Myers JL. Postmortem lung findings in an asthmatic with coronavirus disease 2019 (COVID- 19). Chest 2020 pii: S0012-3692(20)30775-3. doi: 10.1016/j.chest.2020.04.032
13. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 2020;8(5):436-8.
14. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig 2020. Epub 2020/02/26.
15. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv 2020. doi: 10.1101/2020.03.11.987016
16. Simpson JL, Carroll M, Yang IA, Reynolds PN, Hodge S, James AL, et al. Reduced antiviral interferon production in poorly controlled asthma is associated with neutrophilic inflammation and high-dose inhaled corticosteroids. Chest 2016;149(3):704-13.
17. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 2020 pii: S0091-6749(20)30551- 0. doi: 10.1016/j.jaci.2020.04.009
18. Peters MC, Sajuthi S, Deford P, et al. SARS-COV-2 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 2020. doi: 10.1164/rccm.202003-0821OC.
19. Zheng XY, Xu YJ, Guan WJ, Lin LF. Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. Arch Virol 2018;163(4):845-53.
20. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 2010;36(3):646-54.
21. Porter JD, Watson J, Roberts LR, Gill SK, Groves H, Dhariwal J, et al. Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFNaugmenting activity in airway epithelium. J Antimicrob Chemother 2016;71(10):2767-81.
22. Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe outcomes? Allergy 2020. doi: 10.1111/ all.14348.
23. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, doubleblind, placebo-controlled trial. Lancet 2017;390(10095):659- 68.
24. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Available from: www. ginaasthma.org
25. COVID-19 rapid guideline: severe asthma. NICE guideline [NG166]Published date: 03 April 2020.
26. Licskaia C, Yang CL, Ducharmec FM, Radhakrishnand D, Podgerse D, Ramseyf C, et al. Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the COVID-19 pandemic. Canadian J Respir Crit Sleep Med Available from: https://doi.org/10.1080/ 24745332.2020.1754027
27. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY, et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. J Allergy Clin Immunol Pract 2020;8(5):1477-88.e5.
28. Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir Med 2020:105987. doi: 10.1016/j.rmed.2020. 105987
29. McGrath J, O’Toole C, Joyce GBM, Byrne M, MacLoughlin R. Investigation of fugitive aerosols released into the environment during high-flow therapy. Pharmaceutics 2019;11:254.
30. Wittgen BP, Kunst PW, Perkins WR, Lee JK, Postmus PE. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med 2006;19:385-91.
31. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020;395(10225):683-4.
32. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020 Feb 15;395(10223):473-5.
33. Levin M, Morais-Almeida M, Ansotegui IJ, Bernstein J, Chang YS, Chikhladze M, et al. Acute asthma management during SARS-CoV2-pandemic 2020. World Allergy Organ J 2020 May 14:100125. doi: 10.1016/j.waojou.2020.100125.
34. Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkov YA, et al. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med 2017;196(8):985-92.
35. Self-Administration of Xolair Pre-Filled Syringe (PFS) for Asthma during the COVID-19 Pandemic. https://www. gene.com/medical-professionals/medicines/xolair. Accessed 23-Apr-2020
36. http://www.siaaic.org/wp-content/uploads/2020/04/ Documento-di-Indirizzo-SIAAIC.pdf. Accessed 8-Apr-2020.
37. Malipiero G, Paoletti G, Puggioni F, Racca F, Ferri S, Marsala A, et al. An academic allergy unit during COVID-19 pandemic in Italy. J Allergy Clin Immunol 2020 Apr 16:S0091- 6749(20)30489-9. doi: 10.1016/j.jaci.2020.04.003
38. Mitchell P, Leigh R. A drug safety review of treating eosinophilic asthma with monoclonal antibodies. Expert Opin Drug Saf 2019;18(12):1161-70.
39. Agache I, Rocha C, Beltran J, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma. Allergy 2020 Feb 16. doi: 10.1111/all.14235.
40. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380(9842):651-9.
41. FitzGerald JM, Bleecker ER, Nair P, et al; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388(10056):2128-41.
42. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018;378(26):2486-96.
43. Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda LK, et al. COVID-19, asthma, and biologic therapies: What we need to know. World Allergy Organ J 2020 May 16:100126. doi: 10.1016/j.waojou.2020.100126.

APA	Sarioglu N (2020). Asthma and COVID-19: What do we know?. , 141 - 147. 10.5578/tt.69775
Chicago	Sarioglu Nurhan Asthma and COVID-19: What do we know?. (2020): 141 - 147. 10.5578/tt.69775
MLA	Sarioglu Nurhan Asthma and COVID-19: What do we know?. , 2020, ss.141 - 147. 10.5578/tt.69775
AMA	Sarioglu N Asthma and COVID-19: What do we know?. . 2020; 141 - 147. 10.5578/tt.69775
Vancouver	Sarioglu N Asthma and COVID-19: What do we know?. . 2020; 141 - 147. 10.5578/tt.69775
IEEE	Sarioglu N "Asthma and COVID-19: What do we know?." , ss.141 - 147, 2020. 10.5578/tt.69775
ISNAD	Sarioglu, Nurhan. "Asthma and COVID-19: What do we know?". (2020), 141-147. https://doi.org/10.5578/tt.69775

APA	Sarioglu N (2020). Asthma and COVID-19: What do we know?. Tüberküloz ve Toraks, 68(2), 141 - 147. 10.5578/tt.69775
Chicago	Sarioglu Nurhan Asthma and COVID-19: What do we know?. Tüberküloz ve Toraks 68, no.2 (2020): 141 - 147. 10.5578/tt.69775
MLA	Sarioglu Nurhan Asthma and COVID-19: What do we know?. Tüberküloz ve Toraks, vol.68, no.2, 2020, ss.141 - 147. 10.5578/tt.69775
AMA	Sarioglu N Asthma and COVID-19: What do we know?. Tüberküloz ve Toraks. 2020; 68(2): 141 - 147. 10.5578/tt.69775
Vancouver	Sarioglu N Asthma and COVID-19: What do we know?. Tüberküloz ve Toraks. 2020; 68(2): 141 - 147. 10.5578/tt.69775
IEEE	Sarioglu N "Asthma and COVID-19: What do we know?." Tüberküloz ve Toraks, 68, ss.141 - 147, 2020. 10.5578/tt.69775
ISNAD	Sarioglu, Nurhan. "Asthma and COVID-19: What do we know?". Tüberküloz ve Toraks 68/2 (2020), 141-147. https://doi.org/10.5578/tt.69775